Close Menu

NEW YORK (360Dx) – The US Food and Drug Administration on Thursday announced it allowed Beckman Coulter to market ClearLLab Reagents for the detection of several leukemias and lymphomas.

The test, the agency said, is the first authorized by it for use with flow cytometry to detect the cancers. The reagents OK'd by the FDA are ClearLLab B1 (B-cell tube 1), ClearLLab B2 (B-cell tube 2), ClearLLab T1 (T-cell tube 1), ClearLLab T2 (T-cell tube 2), and ClearLLab M (myeloid tube).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.